Alzheimer’s early biomarkers may emerge in the brain as much as ten years before memory problems begin, according to researchers at Johns Hopkins University who report earlier deterioration in two regions long before the hippocampus shows pronounced damage.
The team says earlier detection could allow clinicians to intervene when treatments have the best chance of preserving cognition.
By reviewing hundreds of brain scans, investigators found that the entorhinal cortex and amygdala, areas critical to memory and emotion, lose tissue earlier than the hippocampus. The pattern could reshape how clinicians track the disease and identify it before substantial cognitive decline.
“We have found that there are early changes in the brain manifesting the clinical biomarkers of atrophy as much as a decade before there are clinical symptoms,” said senior author Michael Miller, a biomedical engineer. He added that the long preclinical window underscores the promise of treating neurodegeneration years before memory symptoms emerge.
The findings appear in NeuroImage Reports and are being presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience.
Detecting Alzheimer’s early biomarkers before memory loss
Alzheimer’s, the leading cause of dementia worldwide, develops silently for years. Researchers view this pre-symptomatic period as a key opportunity for interventions that might better protect memory and other cognitive abilities.
Realizing that potential depends on reliable methods to identify the condition in its earliest stages. Biomarkers, measurable biological signals of disease presence or progression, are central to this effort.
In Alzheimer’s research, such markers could reveal who is developing pathology before symptoms become apparent. “Our goal is to be able to treat individuals before the symptoms of Alzheimer’s disease develop so that they may be delayed or even stopped,” said Marilyn Albert, co-author and director of the Johns Hopkins Alzheimer’s Disease Research Center.
Two regions show earlier warning signs than the hippocampus
To pinpoint the earliest detectable changes, researchers analyzed hundreds of magnetic resonance imaging and positron emission tomography scans from two independent cohorts: the Alzheimer’s Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study.
The datasets tracked participants across the disease spectrum, including asymptomatic individuals, people with cognitive impairment, and patients who later died from Alzheimer’s.
Across both cohorts, the entorhinal cortex and amygdala showed greater relative tissue loss early on than the hippocampus, a region that has traditionally been the primary focus of Alzheimer’s imaging due to its central role in memory.
The entorhinal cortex is key to retrieving stored memories, and the amygdala supports emotional memory and processing. Their earlier shrinkage suggests that evaluating these structures alongside the hippocampus could reveal earlier signs of disease than hippocampal assessment alone.
Brain atrophy aligns with tau pathology
The team also linked gray matter loss to tau, a protein strongly associated with Alzheimer’s. Normally, tau stabilizes the internal structure of neurons.
In Alzheimer’s, abnormal tau accumulates and forms tangles that disrupt brain function. Using PET imaging and digital pathology, the researchers found that regions with gray matter atrophy overlapped with areas showing tau-related changes.
Because gray matter contains dense neuron cell bodies that process information, this overlap supports the idea that early changes in the entorhinal cortex and amygdala could serve as useful indicators of nascent disease.
The investigators say measuring tissue loss in both regions, rather than focusing primarily on hippocampal changes, could ultimately improve predictions about who is most likely to develop cognitive decline. As advanced imaging becomes more accessible, clinicians might incorporate these measures into routine assessments, particularly for people with family histories or other risk factors.
Co-author Meaghan Morris, a neuropathologist, said better risk stratification could enable earlier treatment to slow disease progression. Related research exploring early-stage disease markers includes work such as pantethine for psoriasis shows promise in early research.
A path toward earlier intervention
The results are preliminary for clinical use. While the study identifies potential early imaging biomarkers, it does not yet establish a diagnostic test that predicts Alzheimer’s years in advance.
Next steps include probing these regions at finer scales to map the molecular milieu around abnormal tau and to understand how those processes drive progressive tissue loss. Clarifying the underlying biology could reveal targets for therapies aimed at interrupting the disease before extensive damage occurs.
“Our future work is to better show the molecular neighborhoods associated with these tau protein changes as localized by these clinical biomarkers of atrophy,” Miller said. “Once we know more about the molecular neighborhoods, we can develop therapies.”